Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Naviter Wealth LLC

Naviter Wealth LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 616.1% during the fourth quarter, HoldingsChannel reports. The firm owned 3,595 shares of the medical equipment provider’s stock after purchasing an additional 3,093 shares during the quarter. Naviter Wealth LLC’s holdings in Intuitive Surgical were worth $1,876,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently modified their holdings of ISRG. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical in the 4th quarter valued at approximately $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical in the fourth quarter worth $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at $31,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical during the 3rd quarter worth $33,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Intuitive Surgical in the 4th quarter valued at about $36,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of research analyst reports. Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Piper Sandler reiterated an “overweight” rating and issued a $670.00 price objective (up from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. Jefferies Financial Group upped their target price on Intuitive Surgical from $475.00 to $575.00 in a research note on Monday, January 27th. Barclays raised their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a research note on Monday, January 27th. Finally, BTIG Research lifted their price target on Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. The trade was a 27.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 3,031 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $577.30, for a total transaction of $1,749,796.30. Following the sale, the executive vice president now directly owns 353 shares of the company’s stock, valued at approximately $203,786.90. This represents a 89.57 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,579 shares of company stock worth $7,756,844. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Stock Down 3.8 %

Shares of NASDAQ ISRG opened at $518.26 on Friday. The stock’s 50 day moving average price is $571.36 and its two-hundred day moving average price is $531.53. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The stock has a market capitalization of $184.59 billion, a P/E ratio of 80.85, a PEG ratio of 5.85 and a beta of 1.43.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.